ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition